Purchase this article with an account.
R. A. Adelman, F. Lu, Z. Hu, J. Sinard, A. Garen; Intravenous Factor VII-Verteporfin for Targeted Photodynamic Therapy in Experimental Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3091.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of factor VII (fVII)-verteporfin for targeted photodynamic therapy (TPT) as compared to non-targeted photodynamic therapy (PDT) in a rat model of choroidal neovascularization (CNV). fVII-verteporfin binds tightly and specifically to tissue factor, which is expressed on endothelial cells of CNV but not normal vasculature.
In Brown-Norway rats CNV lesions were induced by laser photocoagulation of the retina. After 3 weeks, the rats were injected intravenously with fVII-verteporfin (0.5 mg/m2 and 1.0 mg/m2) or verteporfin (6.0 mg/ m2). Randomly selected lesions were treated with 689 nm laser 30 or 60 minutes later. Lesions were evaluated by fundus photography, fluorescein angiography and histopathology.
The rats injected with verteporfin showed leakage in 75% of the CNV lesions on day 7 and 100% of lesions on day 14. The rats injected with fVII-verteporfin at a dose of 0.5 mg/m2 showed leakage in 33% and 36% of the CNV lesions on day 7 and day 14 respectively. When the dose was increased to 1.0 mg/m2, leakage was detected in 25% and 23% of the CNV lesions on day 7 and day 14 respectively. No ocular side effect was detected by histopathologic evaluation.
The frequency of leakage in CNV lesions was significantly reduced using fVII-verteporfin for targeted PDT as compared to non-targeted PDT. The efficacious dose with fVII-verteporfin was about 1/10th of the dose usually used with verteporfin. Using fVII-verteporfin for targeted PDT may improve the efficacy and safety of PDT for treating choroidal neovascularization.
This PDF is available to Subscribers Only